Stompór Tomasz
Tomasz Stompór, Department of Nephrology, Hypertension and Internal Medicine, University of Warmia and Mazury, 10-561 Olsztyn, Poland.
World J Cardiol. 2014 Apr 26;6(4):115-29. doi: 10.4330/wjc.v6.i4.115.
Arterial calcification is a well-recognized complication of advanced atherosclerosis. Chronic kidney disease (CKD) is characterized by significantly more pronounced, disseminated and fast-progressing calcification of the vascular system, including the coronary arteries. New computed tomography-based imaging techniques allow for the noninvasive assessment and monitoring of calcification in different vascular sites. Coronary artery calcification (CAC) develops early in the course of CKD and is tightly associated with mineral and bone disorders, which include but are not limited to secondary hyperparathyroidism. In this review, recent data on the pathogenesis of CAC development and progression are discussed, with a special emphasis on fibroblast growth factor 23 and its co-receptor, klotho. The prevalence, progression and prognostic significance of CAC are reviewed separately for patients with end-stage renal disease treated with dialysis, kidney transplant recipients and patients with earlier stages of CKD. In the last section, therapeutic considerations are discussed, with special attention paid to the importance of treatment that addresses mineral and bone disorders of CKD.
动脉钙化是晚期动脉粥样硬化公认的并发症。慢性肾脏病(CKD)的特征是血管系统,包括冠状动脉,出现明显更显著、弥漫且进展迅速的钙化。基于计算机断层扫描的新型成像技术可对不同血管部位的钙化进行无创评估和监测。冠状动脉钙化(CAC)在CKD病程早期就会出现,并且与矿物质和骨代谢紊乱密切相关,这些紊乱包括但不限于继发性甲状旁腺功能亢进。在本综述中,我们讨论了CAC发生和进展的发病机制的最新数据,特别强调了成纤维细胞生长因子23及其共受体α-klotho。分别对接受透析治疗的终末期肾病患者、肾移植受者以及CKD早期患者的CAC患病率、进展情况和预后意义进行了综述。在最后一部分,我们讨论了治疗方面的考虑因素,特别关注针对CKD矿物质和骨代谢紊乱的治疗的重要性。